Table 1 Baseline and clinical characteristics of the CP-group and propensity-matched nCP-group

Baseline (n, %)

age group

60+

287

70,7

884

72,6

0,035

50–59

58

14,3

142

11,7

0,013

40–49

39

9,6

133

10,9

0,075

30–39

17

4,2

17

1,4

< 0.001

0–30

5

1,2

42

3,4

N/A

sex

males

233

57.4

853

70.0

N/A

females

173

42.6

365

30.0

< 0.001

Comorbidities (n, %)

body mass index ≥ 30

168

41.0

484

39.7

0.559

cardiovascular diseases

277

68.2

827

67.9

0.902

cardiomyopathy

4

1.0

6

0.5

0.272

heart failure

34

8.4

152

12.5

0.025

hypertension

265

65.3

820

67.3

0.447

coronary artery disease

51

12.6

161

13.2

0.734

diabetes mellitus

127

31.3

487

40.0

0.010

smoking

146

36.0

449

36.9

0.914

COVID-19 severity (n, %)

ACTT-1 on admission

3

45

11.1

142

11.7

N/A

4

129

31.8

400

32.8

0.931

5

194

47.8

580

47.6

0.776

6

34

8.4

96

7.9

0.672

7

4

1.0

0

0.0

< 0.001

ACTT-1, when considered administration

1

0

0

3

0.2

N/A

2

0

0

2

0.2

1.000

3

35

8.6

109

8.9

0.336

4

104

25.6

333

27.3

0.343

5

153

37.7

474

38.9

0.330

6

75

18.5

217

17.8

0.307

7

37

9.1

79

6.5

0.208

8

2

0.5

1

0.1

0.060

Day from symptoms at considered administration ≤ 3

100

24,6

329

27.0

0.346

Day from symptoms at considered administration > 3

306

75.4

889

73.0

N/A

Outcome

in-hospital survival (n, %)

320

78.8

751

61.7

< 0.001

length of hospital stay (days)

15.45

N/A

15.25

N/A

N/A